Glutamate Modulators to Treat Neurological and Psychiatric Disorders
Overview
Prof. Sandhya Kortagere of Drexel University has developed glutamate transport modulators for treating neurological disorders caused by glutamate dysregulation. These drugs increase clearance of the neurotransmitter glutamate by cells containing GLT-1, an important modulator of the glutamatergic system. Administration of these compounds can prevent and treat neurological disorders, including Parkinson’s, Alzheimer’s, Huntington’s disease, ALS, stroke, epilepsy and Schizophrenia, which are associated with excessive extracellular glutamate. These compounds target GLT-1 activity, aiming to regulate glutamate transmission and alleviate symptoms of various neurological conditions, without interfering with the neuronal glutamate receptors.
Market Applications
- Pharmaceutical therapy for neuropsychiatric disorders including Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, stroke, epilepsy, and schizophrenia.
- Research and development in the areas of glutamate regulation and neurological disorders.
Key Advantages
- Targeted modulation of GLT-1 activity to regulate glutamate levels.
- Potential to prevent, treat, or ameliorate neurological disorders associated with glutamate dysregulation.
- Minimization of side effects as compared to traditional therapies targeting neuronal receptors.
Problems Solved
- Excessive extracellular glutamate concentrations are associated with many neuropsychiatric conditions.
- Limited efficacy and significant side effects of current small molecule therapies targeting neuronal receptors.
- Lack of treatments addressing the dysregulation of glutamate transporters like GLT-1.
Intellectual Property and Commercialization Opportunities
Published PCT Application WO 2023/146831 A1
Available for licensing, please contact our office for additional information